Patents by Inventor Philippe Julien

Philippe Julien has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NANOPARTICLE PLATFORM FOR ANTIBODY AND VACCINE DELIVERY
    Publication number: 20250114475
    Abstract: A fusion protein comprises a nanocage monomer; and an antibody or fragment thereof linked to the nanocage monomer, the antibody or fragment thereof comprising a first member of a binding pair; wherein a plurality of the fusion proteins self-assemble to form a nanocage in which a plurality of the antibodies or fragments thereof decorate the exterior surface of the nanocage, whereby the first member of the binding pair is exposed for interacting with a second member of a binding pair.
    Type: Application
    Filed: September 16, 2024
    Publication date: April 10, 2025
    Inventors: Jean-Philippe Julien, Taylor Sicard, Anthony Semesi, Bebhinn Treanor, Tiantian Zhao, Edurne Rujas Diez
  • Nanoparticle platform for antibody and vaccine delivery
    Patent number: 12214052
    Abstract: A fusion protein comprises a nanocage monomer; and an antibody or fragment thereof linked to the nanocage monomer, the antibody or fragment thereof comprising a first member of a binding pair; wherein a plurality of the fusion proteins self-assemble to form a nanocage in which a plurality of the antibodies or fragments thereof decorate the exterior surface of the nanocage, whereby the first member of the binding pair is exposed for interacting with a second member of a binding pair.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: February 4, 2025
    Assignees: The Hospital for Sick Children, The Governing Council of the University of Toronto
    Inventors: Jean-Philippe Julien, Taylor Sicard, Anthony Semesi, Bebhinn Treanor, Tiantian Zhao, Edurne Rujas Diez
  • MODIFIED MULTABODY CONSTRUCTS, COMPOSITIONS, AND METHODS TARGETING SARS-COV-2
    Publication number: 20250011397
    Abstract: A self-assembled polypeptide complex comprises: (a) one or more fusion proteins comprising a nanocage monomer or subunit thereof linked to an Fc polypeptide, and (b) one or more fusion proteins comprising a nanocage monomer or subunit thereof linked to a SARS-COV-2 binding moiety; wherein a plurality of the fusion proteins self-assemble to form a nanocage.
    Type: Application
    Filed: October 14, 2022
    Publication date: January 9, 2025
    Inventors: Jean-Philippe Julien, Arif Jetha, Clare Burn Aschner, Krithika Muthuraman
  • MODIFIED MULTABODY CONSTRUCTS, COMPOSITIONS, AND METHODS
    Publication number: 20250002564
    Abstract: A fusion protein comprises a nanocage monomer or subunit thereof linked to an Fc polypeptide, wherein the Fc polypeptide comprises an IgG4 Fc chain with a mutation at one or more of positions 228, 234, 235, 237, and 238, according to EU numbering, and wherein a plurality of the fusion proteins self-assemble to form a nanocage.
    Type: Application
    Filed: October 14, 2022
    Publication date: January 2, 2025
    Inventors: Jean-Philippe Julien, Arif Jetha, Clare Burn Aschner, Krithika Muthuraman
  • DR5-TARGETING MULTABODIES FOR THE TREATMENT OF CANCER
    Publication number: 20240409652
    Abstract: Self-assembled polypeptide complexes comprising 1) fusion polypeptides comprising Fc polypeptides linked to nanocage monomers or subunits thereof and 2) fusion polypeptides comprising an antigen-binding antibody fragment capable of binding to DR5.
    Type: Application
    Filed: September 13, 2022
    Publication date: December 12, 2024
    Inventors: Jean-Philippe Julien, Edurne Rujas Diez, Joanne Hulme, Peter Edward Bayliss, Xinwen He, Melissa Beilschmidt
  • OPTIMIZED MULTABODY CONSTRUCTS, COMPOSITIONS, AND METHODS
    Publication number: 20240400704
    Abstract: Optimized self-assembled poly peptide complexes comprising 1) fusion polypeptides comprising Fc polypeptides linked to nanocage monomers or subunits thereof and 2) fusion polypeptides comprising an antigen-binding antibody fragment.
    Type: Application
    Filed: September 13, 2022
    Publication date: December 5, 2024
    Inventors: Jean-Philippe Julien, Edurne Rujas Diez, Joanne Hulme, Peter Edward Bayliss, Xinwen He, Melissa Beilschmidt
  • MULTABODY CONSTRUCTS, COMPOSITIONS, AND METHODS
    Publication number: 20240317842
    Abstract: In aspects, a fusion protein comprises a nanocage monomer or a subunit thereof linked to an Fc monomer, wherein a plurality of the fusion proteins are capable of self-assembling to form a nanocage comprising one or more Fc dimers. In aspects, a fusion protein comprises a nanocage monomer or a subunit thereof linked to an Fc monomer or scFc fragment at the C-terminus of the nanocage monomer or subunit thereof, wherein a plurality of the fusion proteins are capable of self-assembling to form a nanocage.
    Type: Application
    Filed: January 28, 2022
    Publication date: September 26, 2024
    Inventors: Jean-Philippe Julien, Edurne Rujas Diez
  • POLYPEPTIDES TARGETING DR4 AND/OR DR5 AND RELATED COMPOSITIONS AND METHODS
    Publication number: 20240182544
    Abstract: A fusion protein comprises a nanocage monomer or a subunit thereof linked to a DR4 and/or DR5 antigen-binding moiety, wherein a plurality of the fusion proteins self-assemble to form a nanocage. Also described is a nanocage comprising the fusion protein and related compositions as well as methods and uses for treating and/or preventing cancer.
    Type: Application
    Filed: November 25, 2021
    Publication date: June 6, 2024
    Inventors: Jean-Philippe Julien, Edurne Rujas Diez
  • SARS-COV-2 CONSTRUCTS, VACCINES, AND METHODS
    Publication number: 20240100149
    Abstract: Described herein is an anti-class II MHC antibody fused to a SARS-CoV-2 antigen. Also described is a vaccine comprising the antibody and methods for treating and/or preventing SARS-CoV-2, wherein the methods comprise administering the antibody to a subject in need thereof. In typical aspects, the vaccine is free of an adjuvant.
    Type: Application
    Filed: November 5, 2021
    Publication date: March 28, 2024
    Inventors: Jean-Philippe JULIEN, Audrey KASSARDJIAN, Brian BARBER
  • IMMUNOGENIC PEPTIDES, COMPOSITIONS, AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF MALARIA
    Publication number: 20230372461
    Abstract: Described herein is an immunogenic fusion protein comprising: an immunogenic peptide or an immunogenic variant thereof, the immunogenic peptide comprising the following motifs: —KQPAa; QPAKa; PAKQa; or AKQPa; —NPDPb; PNPDb; DPNPb; or PNPDb; —NANPc; ANPNc; NPNAc; or PNANc; —NVDPd; VDPNd; DPNVd; or PNVDd; and —NANPe; ANPNe; NPNAe; or PNANe. wherein a, b, c, d, and e are each independently 0 or greater and wherein a±b±c±d±e is at least 2; and a nanocage monomer peptide.
    Type: Application
    Filed: October 9, 2020
    Publication date: November 23, 2023
    Inventors: Jean-Philippe Julien, Stephen Scally, Katherine Prieto, Hedda Wardemann, Julia Ludwig, Rajagopal Murugan, Giulia Costa, Elena Levashina
  • MULTI-VALENT AND MULTI-SPECIFIC NANOPARTICLE PLATFORMS AND METHODS
    Publication number: 20230145060
    Abstract: A fusion protein comprises a first nanocage monomer subunit of a nanocage monomer; and a bioactive moiety linked to the first nanocage monomer subunit; wherein the fusion protein self-assembles with a protein comprising a second nanocage monomer subunit to form a nanocage monomer.
    Type: Application
    Filed: July 31, 2020
    Publication date: May 11, 2023
    Inventors: Jean-Philippe Julien, Edurne Rujas Diez, Bebhinn Treanor, Tiantian Zhao
  • ANTIBODIES AGAINST LIF AND USES THEREOF
    Publication number: 20230042095
    Abstract: Described herein are antibodies that target Leukemia Inhibitory Factor (LIF). Also described herein are uses of these antibodies for the treatment of cancer.
    Type: Application
    Filed: June 23, 2022
    Publication date: February 9, 2023
    Inventors: Joan SEOANE SUAREZ, Judit ANIDO FOLGUEIRA, Johan FRANSSON, Jean-Philippe JULIEN, Swetha RAMAN
  • Antibodies against LIF and uses thereof
    Patent number: 11390670
    Abstract: Described herein are antibodies that target Leukemia Inhibitory Factor (LIF). Also described herein are uses of these antibodies for the treatment of cancer.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: July 19, 2022
    Assignees: MEDIMMUNE LIMITED, FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGIC, FUNDACIO PRIVADA INSTITUCIO CATALANA DE RECERCA I
    Inventors: Joan Seoane Suarez, Judit Anido Folgueira, Johan Fransson, Jean-Philippe Julien, Swetha Raman
  • IMMUNE COMPOSITION, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF
    Publication number: 20210290759
    Abstract: A prokaryotic expression system or a recombinant adenovirus system is used to highly efficiently express VZV envelope gE glycoprotein and the flagellin fusion protein thereof. The produced recombinant gE protein, gE flagellin fusion protein and recombinant adenovirus vector, or composition thereof is used to immunize a mouse so as to promote the body to generate gE and VZV-specific antibody titer, as well as gE-specific and VZV-specific cell immunity.
    Type: Application
    Filed: March 29, 2021
    Publication date: September 23, 2021
    Inventors: Ting MU, Ping ZHAO, Long XU, Yang XIAO, Jean-philippe JULIEN, Yue WU, Liang XIE, Xueting CHEN, Qi LIU, Charles Dwo Yuan SIA, Pele Choi Sing CHONG, Michel KLEIN, Linsen DU, Ke WU
  • NANOPARTICLE PLATFORM FOR ANTIBODY AND VACCINE DELIVERY
    Publication number: 20200179532
    Abstract: A fusion protein comprises a nanocage monomer; and an antibody or fragment thereof linked to the nanocage monomer, the antibody or fragment thereof comprising a first member of a binding pair; wherein a plurality of the fusion proteins self-assemble to form a nanocage in which a plurality of the antibodies or fragments thereof decorate the exterior surface of the nanocage, whereby the first member of the binding pair is exposed for interacting with a second member of a binding pair.
    Type: Application
    Filed: August 3, 2018
    Publication date: June 11, 2020
    Inventors: Jean-Philippe Julien, Taylor Sicard, Anthony Semesi, Bebhinn Treanor, Tiantian Zhao, Edurne Rujas Diez
  • ANTIBODIES AGAINST LIF AND USES THEREOF
    Publication number: 20190352389
    Abstract: Described herein are antibodies that target Leukemia Inhibitory Factor (LIF). Also described herein are uses of these antibodies for the treatment of cancer.
    Type: Application
    Filed: December 18, 2017
    Publication date: November 21, 2019
    Inventors: Joan SEOANE SUAREZ, Judit ANIDO FOLGUEIRA, Johan FRANSSON, Jean-Philippe JULIEN, Swetha RAMAN
  • ANTIBODIES AGAINST LIF AND USES THEREOF
    Publication number: 20180243414
    Abstract: Described herein are antibodies that target Leukemia Inhibitory Factor (LIF). Also described herein are uses of these antibodies for the treatment of cancer.
    Type: Application
    Filed: December 18, 2017
    Publication date: August 30, 2018
    Inventors: Joan Seoane SUAREZ, Judit Anido FOLGUEIRA, Johan FRANSSON, Jean-Philippe JULIEN, Swetha RAMAN
  • ANTIBODIES AGAINST LIF AND USES THEREOF
    Publication number: 20180169233
    Abstract: Described herein are antibodies that target Leukemia Inhibitory Factor (LIF). Also described herein are uses of these antibodies for the treatment of cancer.
    Type: Application
    Filed: January 26, 2018
    Publication date: June 21, 2018
    Inventors: Joan Seoane SUAREZ, Judit Anido FOLGUEIRA, Johan FRANSSON, Jean-Philippe JULIEN, Swetha RAMAN
  • HIV-1 envelope glycoprotein
    Patent number: 9738688
    Abstract: The present application relates to novel HIV-1 envelope glycoproteins, which may be utilized as HIV-1 vaccine immunogens, and antigens for crystallization, electron microscopy and other biophysical, biochemical and immunological studies for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions, which are formulated into the vaccines of the present invention.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: August 22, 2017
    Assignees: INTERNATIONAL AIDS VACCINE INITIATIVE, THE SCRIPPS RESEARCH INSTITUTE, CORNELL UNIVERSITY
    Inventors: Michael Caulfield, Albert Cupo, Hansi Dean, Simon Hoffenberg, C. Richter King, P. J. Klasse, Andre Marozsan, John P. Moore, Rogier W. Sanders, Andrew Ward, Ian Wilson, Jean-Philippe Julien
  • NOVEL HIV-1 ENVELOPE GLYCOPROTEIN
    Publication number: 20140212458
    Abstract: The present application relates to novel HIV-1 envelope glycoproteins, which may be utilized as HIV-1 vaccine immunogens, and antigens for crystallization, electron micrsocopy and other biophysical, biochemical and immunological studies for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions, which are formulated into the vaccines of the present invention.
    Type: Application
    Filed: November 5, 2013
    Publication date: July 31, 2014
    Applicants: INTERNATIONAL AIDS VACCINE INITIATIVE, THE SCRIPPS RESEARCH INSTITUTE, CORNELL CENTER FOR TECHNOLOGY ENTERPRISE AND COMMERCIALIZATION
    Inventors: Michael Caulfield, Albert Cupo, Hansi Dean, Simon Hoffenberg, C. Richter King, P. J. Klasse, Andre Marozsan, John P. Moore, Rogier W. Sanders, Andrew Ward, Ian Wilson, Jean-Philippe Julien